Ratio Therapeutics is a clinical-phase pharmaceutical company that develops radiopharmaceuticals for solid tumors.
Ratio Therapeutics has raised $70.0M in total funding. The most recent round was Series C. The last funding was announced in July 2026.
Ratio Therapeutics's investors include Eli Lilly, Catalio Capital Management, Bristol-Myers Squibb, Cornell University, Duquesne Family Office.
Ratio Therapeutics is headquartered in Boston, United States.
Ratio Therapeutics is a clinical-phase pharmaceutical company that develops radiopharmaceuticals for solid tumors.
Ratio Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ratio Therapeutics — Funding & Investors." VCBacked, July 31, 2026, https://www.vcbacked.co/company/ratio-therapeutics. Accessed August 6, 2026.
VCBacked. (2026). Ratio Therapeutics — Funding & Investors. Retrieved August 6, 2026, from https://www.vcbacked.co/company/ratio-therapeutics
{{cite web |title=Ratio Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/ratio-therapeutics |website=VCBacked |access-date=August 6, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated